rformance chemicals revenues, which grew at about 4.8 per cent in FY08, to move up substantially due to expansions. Revenues from single super phosphate, which contributed about Rs 80 crore in FY08, are expected to double due to the setting up of a new unit. Considering the growth prospects in its healthcare business, revenues from Draxis, enhancement of capacity at Hollister and higher growth expected in the industrial/performance chemicals business, the company is likely to post revenues of about Rs 3,500 crore for FY09. At Rs 355, the stock is available at 12.4 times its FY10 earnings of Rs 28.65 and should fetch 29 per cent returns over the next 15 months.
Top Section
Explore Business Standard